Abreva and Xeroderma pigmentosum - a phase IV clinical study of FDA data

Summary:

We study 16,329 people who take Abreva or have Xeroderma pigmentosum. No report of Xeroderma pigmentosum is found in people who take Abreva.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 06, 2023

No report is found.

What is Abreva?

Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 16,320 Abreva users for its effectiveness, alternative drugs and more.

What is Xeroderma Pigmentosum?

Xeroderma pigmentosum (impairment of the skin's ability to repair damage from ultraviolet) is found to be associated with 5 drugs and 3 conditions by eHealthMe.

Do you take Abreva and have Xeroderma pigmentosum?

Check whether Xeroderma pigmentosum is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Xeroderma pigmentosum and when was it recovered:

Xeroderma pigmentosum in Abreva

Expand to all the drugs that have ingredients of docosanol:

Xeroderma pigmentosum and drugs with ingredients of docosanol

Alternative drugs to, pros and cons of Abreva:

Abreva (16,320 reports)

Xeroderma pigmentosum treatments and more:

Xeroderma pigmentosum (9 reports)

COVID vaccines that are related to Xeroderma pigmentosum:

All the drugs that are associated with Xeroderma pigmentosum:

Xeroderma pigmentosum

All the conditions that are associated with Xeroderma pigmentosum:

Xeroderma pigmentosum

How the study uses the data?

The study uses data from the FDA. It is based on docosanol (the active ingredients of Abreva) and Abreva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.